The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease

The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02259049

Enrollment

Registered

2014-10-08

Start date

2014-10-31

Completion date

2015-09-30

Last updated

2016-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure

Brief summary

The investigators are observing the effects 2,000 mg of L-tyrosine will have on 24 hour blood pressure fluctuations in individuals with Parkinson's disease.

Detailed description

We will be monitoring 24 hour ambulatory BP and HR in subjects with PD on 3 separate visits. The first visit will be without an intervention to establish a baseline of 24 hour BP fluctuations. One week later the subject will be given either L-tyrosine (2,000 mg) with B6 (10 mg) or a sugar pill. We will monitor 24 hour BP and HR after supplementation. One week later the subject will repeat the same procedures with either supplement or placebo. This is a total of 3 visits with 24 hour ambulatory BP and HR monitoring.

Interventions

DIETARY_SUPPLEMENTL-tyrosine

Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.

DIETARY_SUPPLEMENTSugar Pill

Each subject will receive a sugar pill BID for 24 hours.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 84 Years

Healthy volunteers

Inclusion criteria

1. All subjects must have a diagnosis of PD by a licensed neurologist according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (UKPDBB).(Goetz, 2010) The UKPDBB is a 3 step diagnostic tool which defines inclusion and

Exclusion criteria

for diagnosing PD 2. between 35 and 79 years of age 3. mentally able to participate in the study

Design outcomes

Primary

Measure	Time frame
Blood Pressure	24 hours

Secondary

Measure	Time frame
Heart Rate	24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026